Loading...
Market
Main reason for delay/failure of Risky Research Review Act by end of 2024?
2
Anthony Fauci•Ralph Baric•Baric•Wuhan Institute of Virology•NIAID•Rand Paul•Fauci•Congress•EcoHealth Alliance•National Institutes of Health•NIH•Paul•Gary Peters•Risky Research Review Act
Resolution / Starting Odds
Lack of bipartisan support • 25%
Lobbying by research institutions • 25%
Public opposition • 25%
Other • 25%
Senate records, media analysis, and expert commentary
Story
Senators Push for Stricter Oversight After Fauci's February 2020 Gain-of-Function Meeting
Oct 9, 2024, 06:21 PM
Dr. Anthony Fauci met with virologist Ralph Baric in February 2020 to discuss Gain-of-Function research and the regulatory oversight of Baric's work with the Wuhan Institute of Virology, which had not been properly regulated by the National Institute of Allergy and Infectious Diseases (NIAID). This meeting highlighted the need for stricter oversight and regulation of such research. Senator Rand Paul has been vocal about the risks associated with Gain-of-Function research and has accused Fauci of lying to Congress about the involvement of Baric and EcoHealth Alliance in risky COVID-19 research funded by the National Institutes of Health (NIH). In response, Paul, along with Senator Gary Peters, has introduced the bipartisan Risky Research Review Act, which aims to prevent future lab-generated pandemics by ensuring more stringent review processes for high-risk research. Advocacy groups are urging the public to support the bill to safeguard against future pandemics and are calling for its passage by unanimous consent.
View original story
Similar markets
Yes • 50%
No • 50%
Pass • 33%
Fail • 33%
Postponed • 33%
Supportive • 25%
Opposed • 25%
Mixed • 25%
No significant reaction • 25%
Budgetary concerns • 25%
Political disagreements • 25%
Procedural issues • 25%
Other reasons • 25%
Democrats • 25%
Republicans • 25%
Bipartisan issues • 25%
Other reasons • 25%
Regulatory issues • 25%
Supply chain issues • 25%
Funding issues • 25%
Other • 25%
Debt ceiling increase • 25%
Disaster relief funding • 25%
Economic assistance for farmers • 25%
Other • 25%
Study published • 25%
NIH takes action • 25%
Congressional hearing held • 25%
No significant outcome • 25%
Policy change on publication mandates • 25%
No policy change • 25%
Public apology or statement from NIH • 25%
Other outcome • 25%
Study published without consequences • 25%
Study published with consequences for Dr. Olson-Kennedy • 25%
Study remains unpublished • 25%
Other outcome • 25%
Regulatory Issues • 25%
Funding Challenges • 25%
Lack of Participation • 25%
Other • 25%
